SCHEMBL10566679

SCHEMBL10566679

COC(=O)c1sc(Cl)cc1N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.60
MAPT P10636 6/20 0.60
NPC1 O15118 3/20 0.60
CASP3 P42574 2/20 0.60
RAB9A P51151 2/20 0.60
SENP8 Q96LD8 2/20 0.60
SENP7 Q9BQF6 2/20 0.60
SENP6 Q9GZR1 2/20 0.60
IKBKB O14920 1/20 0.53
ABL1 P00519 1/20 0.46
GAA P10253 4/20 0.44
HSD17B10 Q99714 7/20 0.43
ALDH1A1 P00352 7/20 0.43
HPGD P15428 5/20 0.43
ALOX15 P16050 2/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
GLA P06280 3/20 0.42
ATM Q13315 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31120455 0.98 KDM4E (0.59) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL9529269 0.81 TSHR (0.45) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL27547199 0.81 MAPT (0.42) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL166726 0.79 MAPT (0.54) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL26281532 0.79 KMT2A (0.44) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL28175472 0.79 MAPT (0.44) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL3239031 0.79 KDM4E (0.54) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL24523710 0.78 KDM4E (0.53) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL102283 0.78 KDM4E (0.53) KDM4EMAPTNPC1CASP3RAB9A
SCHEMBL14419258 0.78 GAA (0.44) KDM4EMAPTNPC1CASP3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617772-B2 Hydroxypyridine HSD17B13 inhibitors and uses thereof INIPHARM, INC. (US) 2026-05-05 US disclosed
US-20240208929-A1 HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2024-06-27 US disclosed
US-20240208929-A1 HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2024-06-27 US disclosed
US-20240208929-A1 HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2024-06-27 US disclosed
EP-4320111-A1 HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2024-02-14 EP disclosed
CN-117024441-A MAT2A inhibitor 武汉人福创新药物研发中心有限公司 2023-11-10 CN disclosed
WO-2022216626-A1 HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2022-10-13 WO disclosed
EP-3152207-B1 PYRIDOPYRIMIDINEDIONE DERIVATIVES AS SUPPRESSORS OF NON-SENS MUTATIONS NOVARTIS AG (CH) 2019-05-08 EP disclosed
US-9884862-B2 Pyridopyrimidinedione derivatives NOVARTIS AG (CH) 2018-02-06 US disclosed
US-20170197959-A1 Pyridopyrimidinedione derivatives NOVARTIS AG (CH) 2017-07-13 US disclosed
EP-3152207-A1 PYRIDOPYRIMIDINEDIONE DERIVATIVES Novartis AG (CH) 2017-04-12 EP disclosed
WO-2015186061-A1 PYRIDOPYRIMIDINEDIONE DERIVATIVES NOVARTIS AG (CH) 2015-12-10 WO disclosed
US-20110237599-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-29 US disclosed
US-4797486-A ANTIPROTOZOA AGENTS PFIZER INC. (US) 1989-01-10 US disclosed
US-4725599-A POULTRY PFIZER INC. (US) 1988-02-16 US disclosed
US-4710506-A Antihypertensive thienopyridines THE BOOTS COMPANY PLC (GB) 1987-12-01 US disclosed
EP-0209977-A2 Thienopyridones, processes and intermediates for their preparation and pharmaceutical compositions containing them The Boots Company PLC (GB) 1987-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237599-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 KDM4E 1897/4885MAPT 2336/4885NPC1 2861/4885
US-20170197959-A1 Pyridopyrimidinedione derivatives DPYD, TPMT, CYP2D6 KDM4E 1677/4885MAPT 2347/4885NPC1 3468/4885
US-20240208929-A1 HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B1, HSD17B13 KDM4E 2653/4885MAPT 3557/4885NPC1 496/4885
US-12617772-B2 Hydroxypyridine HSD17B13 inhibitors and uses thereof HSD11B1, HSD17B1, HSD3B1 KDM4E 4079/4885MAPT 4587/4885NPC1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.